A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies

被引：30

作者：

Li, Fubin ^{[1
]}

Ravetch, Jeffrey V. ^{[1
]}

机构：

[1] Rockefeller Univ, Lab Mol Genet & Immunol, 1230 York Ave, New York, NY 10021 USA

来源：

CELL CYCLE | 2012年 / 11卷 / 18期

关键词：

MONOCLONAL-ANTIBODY; RECEPTOR ENGAGEMENT;

D O I：

10.4161/cc.21842

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

引用

页码：3343 / +

页数：2

共 10 条

[1] Signalling pathways of the TNF superfamily: A double-edged sword [J].

Aggarwal, BB .

NATURE REVIEWS IMMUNOLOGY, 2003, 3 (09) :745-756

[2] Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4 [J].

Chuntharapai, A ;

Dodge, K ;

Grimmer, K ;

Schroeder, K ;

Marsters, SA ;

Koeppen, H ;

Ashkenazi, A ;

Kim, KJ .

JOURNAL OF IMMUNOLOGY, 2001, 166 (08) :4891-4898

[3] Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement [J].

Li, Fubin ;

Ravetch, Jeffrey V. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (27) :10966-10971

[4] Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies [J].

Li, Fubin ;

Ravetch, Jeffrey V. .

SCIENCE, 2011, 333 (6045) :1030-1034

[5] Fcγ receptors as regulators of immune responses [J].

Nimmerjahn, Falk ;

Ravetch, Jeffrey V. .

NATURE REVIEWS IMMUNOLOGY, 2008, 8 (01) :34-47

[6] Anti-tumor effects of depleting and non-depleting anti-CD27 monoclonal antibodies in immune-competent mice [J].

Sakanishi, Tamami ;

Yagita, Hideo .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 393 (04) :829-835

[7] Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody [J].

White, Ann L. ;

Chan, H. T. Claude ;

Roghanian, Ali ;

French, Ruth R. ;

Mockridge, C. Ian ;

Tutt, Alison L. ;

Dixon, Sandra V. ;

Ajona, Daniel ;

Verbeek, J. Sjef ;

Al-Shamkhani, Aymen ;

Cragg, Mark S. ;

Beers, Stephen A. ;

Glennie, Martin J. .

JOURNAL OF IMMUNOLOGY, 2011, 187 (04) :1754-1763

[8] An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells [J].

Wilson, Nicholas S. ;

Yang, Becky ;

Yang, Annie ;

Loeser, Stefanie ;

Marsters, Scot ;

Lawrence, David ;

Li, Yun ;

Pitti, Robert ;

Totpal, Klara ;

Yee, Sharon ;

Ross, Sarajane ;

Vernes, Jean-Michel ;

Lu, Yanmei ;

Adams, Cam ;

Offringa, Rienk ;

Kelley, Bob ;

Hymowitz, Sarah ;

Daniel, Dylan ;

Meng, Gloria ;

Ashkenazi, Avi .

CANCER CELL, 2011, 19 (01) :101-113

[9] FcγRs modulate cytotoxicity of anti-fas antibodies:: Implications for agonistic antibody-based therapeutics [J].

Xu, YY ;

Szalai, AJ ;

Zhou, T ;

Zinn, KR ;

Chaudhuri, TR ;

Li, XL ;

Koopman, WJ ;

Kimberly, RP .

JOURNAL OF IMMUNOLOGY, 2003, 171 (02) :562-568

[10] Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors [J].

Zhang, Meili ;

Yao, Zhengsheng ;

Zhang, Zhuo ;

Garmestani, Kayhan ;

Goldman, Carolyn K. ;

Ravetch, Jeffrey V. ;

Janik, John ;

Brechbiel, Martin W. ;

Waldmann, Thomas A. .

BLOOD, 2006, 108 (02) :705-710

← 1 →